First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that high-risk patients ages 50 to 59 be vaccinated for respiratory syncytial ...

ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of ...

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process ...

Hemophilia B, an X-linked disorder resulting from a deficiency in coagulation factor ... and factor IX inhibitor levels. 8 Humoral and cellular responses to the AAV capsid and factor IX were ...

ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of ...

Extending these findings, our research identifies the PD-L1 in pDCs as a critical contributor to humoral immune deficiency, likely through its role in promoting Treg differentiation. These insights ...